#USA #EpiVax #ISPRI toolkit #PANDA Screening #Providence, RI

EpiVax Achieves Major Milestones in 2024

EpiVax, Inc., a premier organization specializing in preclinical immunogenicity risk assessment, has had a remarkable year in 2024. The company has achieved significant milestones through scientific breakthroughs, an expanded range of services, and notable corporate growth. With almost three decades of experience in the field, EpiVax has continuously evolved its methodologies to enhance immunogenicity assessments for biologic and peptide therapeutics.

This year witnessed the launch of several innovative capabilities within their ISPRI™ (Immunogenicity Screening and Protein Re-engineering Interface) Toolkit. The introduction of new service analyses such as ISPRI Downselect™, Quantify™, Analyze™, Evaluate™, Complete™, Optimize™, and Design™ marked a significant enhancement. These offerings cater to different stages of preclinical development, enabling clients to assess and rank individual candidates with increased precision and accuracy. The toolkit also includes Class I analysis for selected gene therapy and CAR-T applications, showcasing EpiVax's adaptability to emerging therapeutic fields.

The PANDA® Screening program has further been expanded to assist sponsors navigating the FDA's Abbreviated New Drug Application (ANDA) pathway, particularly for generic peptides. Enhancements, including advanced adaptive in vitro assays and the introduction of the Innate Immune Response Assay, have positioned EpiVax as a comprehensive resource for generic drug developers. These developments facilitate a one-stop shop experience, incorporating in silico, in vitro, and innate assessments.

In partnership with the FDA, EpiVax embarked on a new contract to create standardized controls for T cell assays, a step aimed at improving the specificity and sensitivity of these critical assessments across the industry. This project reflects EpiVax's commitment to elevating industry standards and enhancing the accuracy of immunogenicity evaluations.

During 2024, the EpiVax team also contributed to the scientific community through the publication of several highly regarded articles, further solidifying their reputation in the immunogenicity assessment domain. This output not only reflects the company's scientific acumen but also its dedication to advancing knowledge within the field.

Due to the expanded services and offerings, EpiVax reported a staggering rise of nearly 60% in immunogenicity risk assessment bookings compared to 2023. This growth was spurred by a doubling of new clients across various service verticals, which includes ISPRI™ Access, ISPRI™ Fee-for-Service, and PANDA® services. In response to this heightened demand, EpiVax increased its workforce by 18%, adding strategically important leadership positions aimed at sustaining this momentum.

Looking ahead to 2025, EpiVax plans to build on its 2024 achievements by integrating state-of-the-art artificial intelligence and machine learning enhancements into existing platforms. The expansion of laboratory capabilities and the recruitment of additional scientific expertise are also on the horizon, promising an exciting future for the company and its partners.

In conclusion, EpiVax's remarkable advancements and dedication to innovation not only reflect the organization's steadfast commitment to excellence in immunogenicity risk assessment but also highlight its pivotal role in shaping the landscape of biologic and peptide therapeutics. The company's proactive approach and innovative spirit position it for continued success in the years to come.

About EpiVax

EpiVax is renowned for its leadership in preclinical immunogenicity assessment and sequence optimization for peptide therapeutics, biologic therapies, and vaccines. The organization collaborates with a diverse array of global partners, including companies, agencies, and academia, to streamline immunogenicity risk evaluation and facilitate rapid vaccine design. For more information, visit www.epivax.com.